吡格列酮对膀胱癌患者机体炎症因子抑制作用的分析  

Inhibitory Effect Analysis of Pioglitazone on Inflammation Factors in Patients with Bladder Cancer

作　　者：刘毅[1] 张旋[2] 李虎宜[1] 张栩亮[1] 权伟合[1] 吴振启[3] 

机构地区：[1]湖北医药学院附属东风总医院泌尿外科,湖北十堰442008 [2]湖北医药学院附属东风总医院妇产科,湖北十堰442008 [3]湖北医药学院,湖北十堰442000

出　　处：《现代检验医学杂志》2015年第2期46-48,共3页Journal of Modern Laboratory Medicine

基　　金：湖北省卫生厅科研基金RAN干扰抑制DNMT基因对人体膀胱癌细胞增殖和凋亡的影响，编号JX3B27。

摘　　要：目的：研究吡格列酮对膀胱癌患者机体炎症因子的抑制作用。方法连续选择2012年2月～2014年2月来湖北医药学院附属东风总医院并诊断为膀胱癌的患者共100例，随机将其分为试验组和对照组各50例，所有患者根据病理分型和分期选择手术、化疗等方案，试验组患者同时接受吡格列酮治疗，15 mg／d×12周；对照组接受常规的治疗方案。对比分析两组患者治疗前后的炎症因子的表达水平，高敏 C 反应蛋白（hs-CRP），肿瘤坏死因子α（TNF-α），白介素（IL-6）以及HOMA-IR 水平，MCP-1和 MIP-1因子的水平的差异性。结果治疗后两组患者的 hs-CRP，TNF-α和 IL-6水平均降低，差异均有统计学意义（P ＜0.05），且试验组降低的更明显，差 异 均 有 统 计 学意义（P ＜0.05）。两组患者的 HOMA-IR， MCP-1和 MIP-1水平均降低，差异均有统计学意义（P ＜0.05），且试验组降低的更明显，差异均有统计学意义（P ＜0.05）。两组患者不良反应率的比较，差异无统计学意义（P ＞0.05）。结论吡格列酮可能通过降低膀胱癌患者的炎症因子如 hs-CRP，TNF-α，IL-6，HOMA-IR，MCP-1和 MIP-1水平提高临床效果，改善预后。Objecitve To study the inhibitory effect of pioglitazone on inflammation factors in patients with bladder cancer. Methods A total of 100 consecutives diagnosed as bladder cancer from Februray 2013 to Februray 2014 were individed ran-domly into experiment and control groups and each of 50 cases.All patients received the appropriate operation or chemother-apeutic regimens,and the patients in experiment group received pioglitazone （15 mg/d×12 weeks）at the same time.Then to compare expression differences of high-sensitive C reactive protein （hs-CRP）,tumor necrosis factor alpha （TNF-alpha）,in-terleukin （IL-6）and HOMA-IR,MCP-1,MIP-1 levels.Results The levels of hs-CRP,TNF-αand IL-6 in the two groups af-ter treatment were all lower （P 〈0.05）,and in experiment groups they were significantly lower than control group （P 〈0.05）.The levels of HOMA-IR,MCP-1 and MIP-1 in the two groups after treatment were all lower （P 〈0.05）,and in ex-periment groups they were significantly lower than control group（P 〈0.05）.The complication rate in the two groups were no statistical difference （P〉0.05）.Conclusion Pioglitazone could improve clinical effect and prognosis by lowing inflam-mation factors including hs-CRP,TNF-α,IL-6,HOMA-IR,MCP-1 and MIP-1 in patients with bladder cancer.

关 键 词：吡格列酮 膀胱癌 炎症因子 

分 类 号：R737.14[医药卫生—肿瘤] R730.53[医药卫生—临床医学]